AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ AbbVie today announced new data on the investigational use of risankizumab in Crohn s disease, upadacitinib in ulcerative colitis and. | October 3, 2021
AbbVie today announced new data on the investigational use of risankizumab in Crohn's disease, upadacitinib in ulcerative colitis and HUMIRA ® in inflammatory bowel disease will be presented as live presentations and e-Posters at the United European Gastroenterology Week Virtual 2021, to be held October 3-5 . AbbVie is presenting a total of 13 abstracts, across a broad range of studies in IBD, including two .